Adaptimmune Therapeutics PLC — Earnings Release 2018

Aug 2, 2018

8-K 1 a18-18121_18k.htm 8-K

*UNITED STATES SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*Current Report*

*Pursuant to Section 13 or 15(d) of*

*the Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): August 2, 2018

*ADAPTIMMUNE THERAPEUTICS PLC*

(Exact name of registrant as specified in its charter)

England and Wales	1-37368	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

*60 Jubilee Avenue, Milton Park*

*Abingdon, Oxfordshire OX14 4RX*

*United Kingdom*

(Address of principal executive offices, including zip code)

*(44) 1235 430000*

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

SEQ.=1,FOLIO='',FILE='C:\JMS\111398\18-18121-1\task8993174\18121-1-ba.htm',USER='111398',CD='Aug 2 00:13 2018'

*Item 2.02 Results of Operations and Financial Conditions*

On August 2, 2018, Adaptimmune Therapeutics plc (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2018 and providing a business update. The text of the press release is attached as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 2.02 of this Form 8-K, including the attached Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

*Item 9.01 Financial Statements and Exhibits.*

(d) Exhibits.

Exhibit No.	Description of Exhibit
99.1	Press release regarding second quarter 2018 financial results and business update dated August 2, 2018.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\111398\18-18121-1\task8993174\18121-1-ba.htm',USER='111398',CD='Aug 2 00:13 2018'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

/s/ Margaret Henry
Name:	Margaret Henry
Title:	Corporate Secretary

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\111398\18-18121-1\task8993174\18121-1-ba.htm',USER='111398',CD='Aug 2 00:13 2018'